Paeds Vivas · mental-behavioural-and-psychosomatic
Depressive disorders in children and adolescents — branching viva
Branching viva on criteria-based diagnosis, the bipolar screen, suicide-risk assessment, stepped care, fluoxetine as first-line SSRI, and the black-box warning.
On this page
Study tools
Target exams
Opening
Examiner: A 15-year-old is in your clinic with six weeks of low mood, has stopped attending sport, her marks have slipped, she is sleeping badly, and her mother found superficial cuts on her forearm. How do you frame this assessment? [4]
Candidate: I would treat this as a possible depressive disorder and a safety concern first. I would take a structured, multi-informant history — the young person alone for part of it — map symptoms against DSM-5-TR criteria, and do a direct suicide and self-harm risk assessment before discussing treatment. [4]
Branch 1 — diagnosis
Examiner: What criteria make it a major depressive episode rather than ordinary low mood? [4]
Candidate: At least five of the nine symptom groups, including depressed or irritable mood or loss of interest, present for most of the day nearly every day for at least two weeks, with clinically significant impairment, and not better explained by a substance, a medical condition, or bipolar disorder. In this age group irritability can substitute for depressed mood. [4]
Examiner (probe): Why multi-informant? [4]
Candidate: Adolescents often under-report internalising symptoms, parents often under-detect mood, and teachers see function and peer behaviour the family does not. School collateral and parent report sharpen the picture. [4]
Branch 2 — the bipolar screen
Examiner: Before you reach for a drug, what must you exclude? [4]
Candidate: A past or current manic or hypomanic episode. I would ask explicitly about any period of elevated or irritable mood with decreased need for sleep, racing thoughts, grandiosity, and goal-directed overactivity. Giving an SSRI to a young person with undiagnosed bipolar depression risks a mixed state or a manic switch. I would also exclude organic mimics (thyroid, anaemia, substances). [4]
References6ShowHide
- [1]Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet, 2016.PMID 27289172
- [2]March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 2004.PMID 15315995
- [3]Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 2007.PMID 17440145
- [4]Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics, 2018.PMID 29483201
- [5]Goodyer IM, Reynolds S, Barrett B, et al. Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled superiority trial. Lancet Psychiatry, 2017.PMID 27914903
- [6]Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA, 2008.PMID 18314433